Epidemiology of Schizophrenia in Bulgaria

This study has been completed.

Sponsor:

Information provided by:

AstraZeneca

ClinicalTrials.gov Identifier:

NCT00984373

First received: September 24, 2009

Last updated: February 2, 2010

Last verified: February 2010

History of Changes

Tracking Information
First Received Date ^ICMJE	September 24, 2009
Last Updated Date	February 2, 2010
Start Date ^ICMJE	September 2009
Primary Completion Date	November 2009 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00984373 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Epidemiology of Schizophrenia in Bulgaria
Official Title ^ICMJE	Epidemiological Study to Describe Approaches in Diagnosis, Treatment and Social Functioning of Schizophrenic Patients in Bulgaria
Brief Summary	The purpose of this study is to provide accurate, reliable information on schizophrenia clinical management in order to detect unmet medical needs of this disease in terms of: Patient characteristics. Diagnostic and treatment approaches: initial and subsequent.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Time Perspective: Prospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Probability Sample
Study Population	Primary Care Clinic
Condition ^ICMJE	Schizophrenia
Intervention ^ICMJE	Not Provided
Study Group/Cohort (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	440
Completion Date	November 2009
Primary Completion Date	November 2009 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Patients with schizophrenia Above 18 years Signed Informed consent Exclusion Criteria: Below 18 years Consent refused
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Bulgaria

Administrative Information
NCT Number ^ICMJE	NCT00984373
Other Study ID Numbers ^ICMJE	NIS-NBG-SER-2009/1
Has Data Monitoring Committee	No
Responsible Party	MC MD, AstraZeneca
Study Sponsor ^ICMJE	AstraZeneca
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	AstraZeneca
Verification Date	February 2010
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top